Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.82 |
| ▸ | TSHR | P16473 | 4/20 | 0.82 |
| ▸ | POLB | P06746 | 3/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | HTT | P42858 | 1/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.82 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 6/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | CASP1 | P29466 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989330 | 0.90 | MAPT (0.81) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL1038897 | 0.85 | PDE4D (1.00) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL7901380 | 0.85 | LMNA (0.78) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL11381277 | 0.82 | ALDH1A1 (0.80) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL7900419 | 0.81 | PDE4D (0.77) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL8288716 | 0.80 | ALDH1A1 (0.98) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL34468526 | 0.80 | ALDH1A1 (1.00) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL34468571 | 0.80 | CNR2 (0.73) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL3912842 | 0.80 | HSD17B10 (0.65) | HSD17B10MAPTNPSR1LMNAKDM4E | |
| SCHEMBL11368712 | 0.80 | ALDH1A1 (0.80) | HSD17B10MAPTNPSR1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| US-10273214-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010088414-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273214-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | GRIN1, GRIN2A, GRIN2B | HSD17B10 3693/4885MAPT 768/4885NPSR1 67/4885 |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | HSD17B10 3693/4885MAPT 768/4885NPSR1 67/4885 |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | HSD17B10 743/4885MAPT 2107/4885NPSR1 4182/4885 |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | GRIN1, GRIN2A, GRIN2B | HSD17B10 3693/4885MAPT 768/4885NPSR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.